Abstract
Non-vitamin K oral antagonist anticoagulants (NOAC) demonstrated efficiency and safety in several clinical trials. These drugs are a promising alternative to standard anticoagulation therapy. One of them is edoxaban — highly selective, reversible and direct inhibitor of factor Xa. It can be used in states that require anticoagulant prophylaxis and treatment, such as prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism. The following article presents an analysis of clinical trials conducted to evaluate safety and efficiency of edoxaban.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
